Apellis Pharmaceuticals Stock Net Asset

APLS Stock

USD 27.75 0.26 0.95%

Apellis Pharmaceuticals fundamentals help investors to digest information that contributes to Apellis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Apellis Stock. The fundamental analysis module provides a way to measure Apellis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Apellis Pharmaceuticals stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Apellis Pharmaceuticals Company Net Asset Analysis

Apellis Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Net Asset

Current Market Value

-

Current Liabilities

More About Net Asset | All Equity Analysis

Current Apellis Pharmaceuticals Net Asset

788.73 M

Most of Apellis Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apellis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Apellis Net Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Apellis Pharmaceuticals is extremely important. It helps to project a fair market value of Apellis Stock properly, considering its historical fundamentals such as Net Asset. Since Apellis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Apellis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Apellis Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Long Term Debt	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Capital Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.87	-0.86	-0.77	0.69	0.4	0.99	1.0	0.93	0.84	0.97	0.87	0.82	0.88	0.84	-0.85	0.96	-0.82	0.85	-0.5	-0.67
Total Stockholder Equity	0.87		-0.81	-0.69	0.65	0.38	0.79	0.87	0.89	0.95	0.77	0.82	0.61	0.65	0.71	-0.77	0.78	-0.75	0.73	-0.47	-0.6
Net Debt	-0.86	-0.81		0.8	-0.78	-0.33	-0.84	-0.86	-0.92	-0.83	-0.86	-0.86	-0.54	-0.81	-0.56	0.83	-0.79	0.8	-0.84	0.57	0.8
Retained Earnings	-0.77	-0.69	0.8		-0.98	-0.79	-0.76	-0.78	-0.84	-0.76	-0.86	-0.84	-0.46	-0.89	-0.53	0.77	-0.75	0.7	-0.97	0.91	0.96
Accounts Payable	0.69	0.65	-0.78	-0.98		0.77	0.66	0.69	0.8	0.74	0.78	0.82	0.34	0.82	0.41	-0.75	0.64	-0.68	0.92	-0.9	-0.94
Net Receivables	0.4	0.38	-0.33	-0.79	0.77		0.39	0.41	0.48	0.52	0.53	0.61	0.25	0.66	0.31	-0.5	0.41	-0.43	0.67	-0.92	-0.7
Total Liab	0.99	0.79	-0.84	-0.76	0.66	0.39		0.99	0.9	0.77	0.98	0.85	0.84	0.9	0.84	-0.83	0.97	-0.8	0.84	-0.49	-0.66
Total Current Assets	1.0	0.87	-0.86	-0.78	0.69	0.41	0.99		0.93	0.84	0.97	0.88	0.82	0.88	0.84	-0.85	0.96	-0.82	0.85	-0.51	-0.67
Common Stock	0.93	0.89	-0.92	-0.84	0.8	0.48	0.9	0.93		0.89	0.93	0.92	0.59	0.85	0.62	-0.88	0.82	-0.85	0.89	-0.59	-0.76
Net Tangible Assets	0.84	0.95	-0.83	-0.76	0.74	0.52	0.77	0.84	0.89		0.77	0.9	0.62	0.74	0.7	-0.83	0.78	-0.81	0.75	-0.62	-0.67
Property Plant Equipment	0.97	0.77	-0.86	-0.86	0.78	0.53	0.98	0.97	0.93	0.77		0.89	0.76	0.95	0.75	-0.85	0.93	-0.8	0.92	-0.63	-0.77
Capital Surpluse	0.87	0.82	-0.86	-0.84	0.82	0.61	0.85	0.88	0.92	0.9	0.89		0.69	0.92	0.65	-0.95	0.81	-0.93	0.81	-0.67	-0.72
Long Term Debt	0.82	0.61	-0.54	-0.46	0.34	0.25	0.84	0.82	0.59	0.62	0.76	0.69		0.74	0.94	-0.68	0.89	-0.67	0.5	-0.26	-0.29
Long Term Debt Total	0.88	0.65	-0.81	-0.89	0.82	0.66	0.9	0.88	0.85	0.74	0.95	0.92	0.74		0.69	-0.87	0.87	-0.82	0.87	-0.73	-0.78
Net Invested Capital	0.84	0.71	-0.56	-0.53	0.41	0.31	0.84	0.84	0.62	0.7	0.75	0.65	0.94	0.69		-0.63	0.93	-0.61	0.59	-0.35	-0.4
Short Long Term Debt	-0.85	-0.77	0.83	0.77	-0.75	-0.5	-0.83	-0.85	-0.88	-0.83	-0.85	-0.95	-0.68	-0.87	-0.63		-0.78	0.99	-0.74	0.57	0.64
Net Working Capital	0.96	0.78	-0.79	-0.75	0.64	0.41	0.97	0.96	0.82	0.78	0.93	0.81	0.89	0.87	0.93	-0.78		-0.75	0.81	-0.53	-0.66
Short Term Debt	-0.82	-0.75	0.8	0.7	-0.68	-0.43	-0.8	-0.82	-0.85	-0.81	-0.8	-0.93	-0.67	-0.82	-0.61	0.99	-0.75		-0.68	0.49	0.57
Capital Stock	0.85	0.73	-0.84	-0.97	0.92	0.67	0.84	0.85	0.89	0.75	0.92	0.81	0.5	0.87	0.59	-0.74	0.81	-0.68		-0.82	-0.95
Current Deferred Revenue	-0.5	-0.47	0.57	0.91	-0.9	-0.92	-0.49	-0.51	-0.59	-0.62	-0.63	-0.67	-0.26	-0.73	-0.35	0.57	-0.53	0.49	-0.82		0.9
Short Term Investments	-0.67	-0.6	0.8	0.96	-0.94	-0.7	-0.66	-0.67	-0.76	-0.67	-0.77	-0.72	-0.29	-0.78	-0.4	0.64	-0.66	0.57	-0.95	0.9

Click cells to compare fundamentals

Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.

Competition

Predict Apellis Pharmaceuticals

Apellis Total Assets

Total Assets

425.13 Million

At this time, Apellis Pharmaceuticals' Total Assets are comparatively stable compared to the past year.

Based on the recorded statements, Apellis Pharmaceuticals has a Net Asset of 788.73 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.

Apellis Net Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apellis Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics of similar companies.

Apellis Pharmaceuticals is currently under evaluation in net asset category among its peers.

Apellis Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apellis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apellis Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Apellis Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Apellis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Apellis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Apellis Pharmaceuticals' value.

		Shares
Fmr Inc	2024-09-30	2.9 M
Octagon Capital Advisors Lp	2024-06-30	2.9 M
Assenagon Asset Management Sa	2024-09-30	2.1 M
Deutsche Bank Ag	2024-06-30	1.8 M
Jennison Associates Llc	2024-09-30	1.8 M
Geode Capital Management, Llc	2024-06-30	1.8 M
Boxer Capital Llc	2024-09-30	1.7 M
Artal Group S A	2024-06-30	1.5 M
Fiera Capital Corporation	2024-06-30	1.4 M
Wellington Management Company Llp	2024-06-30	16.4 M
Ecor1 Capital, Llc	2024-06-30	11.6 M

Apellis Fundamentals

	Return On Equity	-1.07
	Return On Asset	-0.16
	Profit Margin	(0.35) %
	Operating Margin	(0.24) %
	Current Valuation	3.49 B
	Shares Outstanding	124.39 M
	Shares Owned By Insiders	13.98 %
	Shares Owned By Institutions	97.46 %
	Number Of Shares Shorted	20.79 M
	Price To Earning	(6.94) X
	Price To Book	14.42 X
	Price To Sales	4.83 X
	Revenue	396.59 M
	Gross Profit	69.79 M
	EBITDA	(495.21 M)
	Net Income	(528.63 M)
	Cash And Equivalents	852.8 M
	Cash Per Share	7.76 X
	Total Debt	110.93 M
	Debt To Equity	0.63 %
	Current Ratio	7.57 X
	Book Value Per Share	1.94 X
	Cash Flow From Operations	(594.74 M)
	Short Ratio	7.13 X
	Earnings Per Share	(2.03) X
	Price To Earnings To Growth	(0.30) X
	Target Price	45.75
	Number Of Employees	702
	Beta	0.87
	Market Capitalization	3.45 B
	Total Asset	788.73 M
	Retained Earnings	(2.84 B)
	Working Capital	518.74 M
	Current Asset	115.82 M
	Current Liabilities	5.13 M
	Net Asset	788.73 M

About Apellis Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC